Candel Therapeutics Inc. (CADL)
| Bid | 5.5 |
| Market Cap | 305.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.58M |
| EPS (ttm) | -0.66 |
| PE Ratio (ttm) | -8.43 |
| Forward PE | -8.86 |
| Analyst | Buy |
| Ask | 5.65 |
| Volume | 843,768 |
| Avg. Volume (20D) | 917,267 |
| Open | 5.82 |
| Previous Close | 5.96 |
| Day's Range | 5.52 - 5.91 |
| 52-Week Range | 3.79 - 14.60 |
| Beta | -0.88 |
About CADL
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for CADL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
3 days ago · proactiveinvestors.com
Candel Therapeutics secures RMAT for prostate cancer – ICYMICandel Therapeutics Inc (NASDAQ:CADL) CEO talked with Proactive earlier this week about the company's recent achievements in oncology drug development, with a strong focus on its gene therapy programs...
5 days ago · proactiveinvestors.com
Candel Therapeutics advances toward prostate cancer therapy filing after trial successCandel Therapeutics Inc (NASDAQ:CADL) said on Thursday it plans to seek US approval for its lead cancer drug CAN-2409 in late 2026, after a key Phase 3 prostate cancer trial succeeded and the FDA gran...
3 weeks ago · proactiveinvestors.com
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409Candel Therapeutics Inc (NASDAQ:CADL) announced that the European Medicines Agency (EMA) has granted Orphan Designation to its investigational immunotherapy CAN-2409 for the treatment of pancreatic ca...
1 month ago · proactiveinvestors.com
Candel Therapeutics expands Russell Index presence following 2025 reconstitutionCandel Therapeutics Inc (NASDAQ:CADL) has announced its inclusion in several value-oriented Russell indexes as part of the 2025 Russell US Indexes annual reconstitution. The changes became effective w...
1 month ago · proactiveinvestors.com
Candel Therapeutics announces $15M direct offering to support CAN-2409 launch preparationsCandel Therapeutics Inc (NASDAQ:CADL) has announced a $15 million registered direct offering of common stock, the proceeds of which will support launch readiness, medical affairs, and pre-commercializ...
1 month ago · proactiveinvestors.com
Candel Therapeutics names Charles Schoch as CFO after interim tenureCandel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Charles Schoch as its chief financial officer. Schoch had served as interim CFO since January 2024 and is being elevated to the pe...
